PEGylation of liposome-encapsulated midazolam does not improve the bioavailability of midazolam when administered orally
These findings suggest that liposome encapsulation may reduce the first-pass effect following oral administration, but PEGylation is not expected to improve the bioavailability of orally administered midazolam.
Authors
- Yanyin Lu
- Saki Miyake (ORCID: https://orcid.org/0000-0002-9222-7872)
- Hitoshi Higuchi (ORCID: https://orcid.org/0000-0002-8600-7793)
- Hiroshi Tanimura (ORCID: https://orcid.org/0000-0002-7343-1966)
- Takuya Miyawaki (ORCID: https://orcid.org/0000-0002-6378-2623)
- Shigeru Maeda (ORCID: https://orcid.org/0000-0003-1750-7361)
- Maki Fujimoto
- Yukiko Nishioka (ORCID: https://orcid.org/0000-0002-6264-5694)
- Midori Hamaoka-Inoue
- Hitomi Ujita (ORCID: https://orcid.org/0009-0003-2999-8249)
Institutions
- Tokyo Medical and Dental University (JP)
- Okayama University (JP)
- Okayama University Hospital (JP)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1186/s40360-025-00993-1
- Citations
- 2
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 2.09